172 results on '"Raymakers, Reinier A. P."'
Search Results
2. CCN2 (Cellular Communication Network factor 2) in the bone marrow microenvironment, normal and malignant hematopoiesis
3. EBV-related lymphoma after long-term daratumumab treatment: a case report
4. Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib
5. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis
6. Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential
7. Allogeneic stem cell transplantation in a patient with myelodysplastic syndrome and polyarteritis nodosa: a case report and systematic review
8. Wnt inhibitors reduce the unfolded protein response and enhance bortezomib-induced cell death in multiple myeloma
9. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients
10. High prevalence of adverse prognostic genetic aberrations and unmutated IGHV genes in small lymphocytic lymphoma as compared to chronic lymphocytic leukemia
11. Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma
12. αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies
13. Human mitochondrial ATP-binding cassette transporter ABCB10 is required for efficient red blood cell development
14. Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome
15. Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program
16. Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis
17. Feasibility and efficacy of addition of individualized dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia
18. Abnormal WT1 expression in the CD34-negative compartment in myelodysplastic bone marrow
19. Medium-Chain, Triglyceride-Containing Lipid Emulsions Increase Human Neutrophil β2 Integrin Expression, Adhesion, and Degranulation
20. Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016
21. Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma
22. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis
23. Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in The Netherlands
24. Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution
25. Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib
26. Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis
27. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma
28. Human mitochondrial ATP-binding cassette transporter ABCB10 is required for efficient red blood cell development
29. TLR4-Mediated Podosome Loss Discriminates Gram-Negative from Gram-Positive Bacteria in Their Capacity to Induce Dendritic Cell Migration and Maturation
30. Acquired mutations in TET2 are common in myelodysplastic syndromes
31. The Tetraspanin Protein CD37 Regulates IgA Responses and Anti-Fungal Immunity
32. A Critical Role for Prostaglandin E2 in Podosome Dissolution and Induction of High-Speed Migration during Dendritic Cell Maturation
33. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
34. Medium‐Chain, Triglyceride‐Containing Lipid Emulsions Increase Human Neutrophil β 2 Integrin Expression, Adhesion, and Degranulation
35. Regulation of LFA-1 Expression by CD34 Positive Cells and Inducible Growth Factor Production by Stroma Enable Formation of Bone Marrow Compartments
36. Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial.
37. Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells.
38. Medium-chain, triglyceride-containing lipid emulsions increase human neutrophil beta2 integrin expression, adhesion, and degranulation.
39. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma
40. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study
41. High prevalence of adverse prognostic genetic aberrations and unmutated IGHVgenes in small lymphocytic lymphoma as compared to chronic lymphocytic leukemia
42. A Novel, Essential Control for Clonality Analysis with Human Androgen Receptor Gene Polymerase Chain Reaction
43. Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study
44. Deletion of the multidrug resistance protein MRP1gene in acute myeloid leukemia: the impact on MRP activity
45. Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity
46. Lenalidomide for the Treatment of Relapsed and Refractory Multiple Myeloma
47. High Frequency of Adhesion Defects in B-Lineage Acute Lymphoblastic Leukemia
48. Triggering Noncycling Hematopoietic Progenitors and Leukemic Blasts to Proliferate Increases Anthracycline Retention and Toxicity by Downregulating Multidrug Resistance
49. Induction of LFA-1 on Pluripotent CD34+Bone Marrow Cells Does Not Affect Lineage Commitment
50. Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.